Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.58 |
| ▸ | ITGAV | P06756 | 13/20 | 0.58 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.45 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7379400 | 1.00 | ITGB3 (0.58) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7380249 | 0.93 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7380245 | 0.93 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7377263 | 0.93 | ITGB3 (0.56) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7376050 | 0.91 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7376058 | 0.91 | ITGB3 (0.61) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL241017 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL241018 | 0.91 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7377256 | 0.90 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGA2BITGB5 | |
| SCHEMBL7377253 | 0.90 | ITGB3 (0.72) | ITGB3ITGAVITGB1ITGA2BITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | claimed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |